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A B S T R A C T
The purpose of this study was to quantitatively investigate how conjugation of GSH to different liposomal
formulations influence the brain delivery of methotrexate (MTX) in rats. GSH-PEG liposomal MTX based on
hydrogenated soy phosphatidylcholine (HSPC) or egg yolk phosphatidylcholine (EYPC) and their corresponding
PEG control liposomes were prepared. The brain delivery of MTX after intravenously administering free MTX,
four liposomal formulations or free MTX + empty GSH-PEG-HSPC liposomes was evaluated by performing
microdialysis in brain interstitial fluid and blood. Compared to free MTX with a steady-state unbound brain-to-
plasma concentration ratio (Kp,uu) of 0.10, PEG-HSPC liposomes did not affect the brain uptake of MTX, while
PEG-EYPC liposomes improved the uptake (Kp,uu 1.5, p < 0.05). Compared to PEG control formulations, GSH-
PEG-HSPC liposomes increased brain delivery of MTX by 4-fold (Kp,uu 0.82, p < 0.05), while GSH-coating on
PEG-EYPC liposomes did not result in a further enhancement in uptake. The co-administration of empty GSH-
PEG-HSPC liposomes with free MTX did not influence the uptake of MTX into the brain. This work showed that
the brain-targeting effect of GSH-PEG liposomal MTX is highly dependent on the liposomal formulation that is
combined with GSH, providing insights on formulation optimization of this promising brain delivery platform.
1. Introduction
A critical factor limiting the treatment of brain diseases is the in-
capacity of drugs to reach the brain in sufficient quantities to be ef-
fective, due to the highly restrictive blood-brain barrier (BBB) [1,2].
One possibility to enhance blood-to-brain drug delivery may be to
formulate drugs in nanocarriers like liposomes. An important reason
why liposomal brain delivery is expected to be promising is that it is
possible to functionalize the surface of the liposomes with BBB-tar-
geting ligands to potentially achieve brain-targeted delivery [3,4]. By
choosing a ligand (e.g., antibodies, peptides) specific for proteins or
receptors expressed at the BBB, the liposomes may take advantage of
endogenous BBB-crossing mechanisms and ultimately facilitate drug
delivery into the brain parenchyma [5].
Nutrient transporters like the glutathione transporter, which is ex-
pressed preferentially in the central nervous system (CNS) and the BBB,
is present in all mammalian species and may be utilized to improve
brain delivery [6–8]. Glutathione (GSH) is an endogenous tripeptide
with antioxidant-like properties [9,10]. Additionally, GSH possesses a
well-established and good safety profile when being administered
exogenously [10]. 2-BBB has developed the G-Technology® which uti-
lizes GSH as a targeting ligand conjugated onto PEGylated (PEG) lipo-
somes. GSH-PEG liposomes have been shown to safely improve brain
delivery of various therapeutic agents including small molecular drugs
[9,11], peptide [12] and single domain antibody fragments [13] in
animal models.
GSH-PEG liposomes have been shown to be more beneficial in de-
livering drugs into the brain than non-targeted PEG liposomes. For
example, Rip et al. demonstrated that GSH-PEG liposomal ribavirin led
to up to 5-fold higher unbound drug concentration in the brain com-
pared to PEG control liposomes, while having similar systemic exposure
[14]. Another study showed that the unbound brain level of a fluores-
cence tracer, carboxyfluorescein was increased 4-fold when being de-
livered with GSH-PEG liposomes compared to plain PEG liposomes,
while the total plasma levels were similar [10]. However, the brain-
targeted effect was not observed for GSH-PEG liposomal DAMGO, an
opioid peptide, compared to PEG liposomal DAMGO [15]. Apart from
different payloads, another critical factor that may contribute to the
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distinct effect of GSH-PEG liposomal formulations on brain delivery
between these studies is the different liposomal formulations that are
combined with GSH. In cases where GSH-PEG liposomes were superior
to PEG controls, the formulations contained hydrogenated soy phos-
phatidylcholine (HSPC), while in the study where GSH-PEG liposomes
showed no advantage over PEG control liposomes, egg-yolk phospha-
tidylcholine (EYPC) was the main phospholipid used in the formulation.
Also, our previous study has shown that different formulations of PEG
liposomal methotrexate (MTX) based on HSPC or EYPC, can result in
very different brain delivery of MTX [16]. EYPC based formulation
increased brain uptake of MTX three-fold, while the HSPC based one
had no impact on the uptake at all compared with free MTX. However,
there are no systematic and quantitative studies testing whether or not
formulations with different phospholipids have an impact on the out-
comes of brain-targeted delivery of GSH-PEG liposomes.
In the current study, we therefore used MTX as a model drug, being
suitable for microdialysis and also a good substrate for liposome-en-
capsulation with superior stability both in vitro and in vivo. It explores
whether the brain-targeting effect of GSH-PEG liposomes depends on
the liposomal formulation, providing insights into the formulation op-
timization of this promising brain delivery platform. Two formulations
of GSH-PEG liposomal MTX based on HSPC and EYPC as well as their
corresponding PEG control liposomes were produced. The purpose of
this study was to quantitatively investigate how the conjugation of GSH
may influence brain delivery of MTX in combination with different li-
posomal formulations in rats. To achieve this goal, continuous micro-
dialysis sampling in both blood and striatum combined with regular
blood sampling were performed, which enabled the separation of re-
leased, active drug from drug remaining liposomally encapsulated, and
thereby being able to describe the multiple in vivo processes present.
2. Materials and methods
2.1. Materials
MTX solution for injection (100 mg/mL) was obtained from Leiden
University Medical Center Pharmacy (Leiden, The Netherlands).
Deuterated MTX (MTX-D3) was purchased from Sigma-Aldrich
(Steinheim, Germany). Hydrogenated soy phosphatidylcholine (HSPC)
and egg-yolk phosphatidylcholine (EYPC) were obtained from Lipoid
(Cham, Switzerland). Cholesterol and reduced glutathione (GSH) was
purchased from Sigma-Aldrich (Zwijndrecht, the Netherlands). 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-conjugated polyethylene
glycol MW 2000 (mPEG2000-DSPE) and DSPE-PEG2000-maleimide were
purchased from Laysan Bio Inc. (Alabama, USA). The Ringer solution
was prepared in-house, containing 145 mM NaCl, 0.6 mM KCl, 1.2 mM
CaCl2, 1.0 mM MgCl2 and 0.1 mM ascorbic acid in 2.0 mM phosphate
buffer (pH 7.4). Acetonitrile (ACN) and formic acid (FA) were of ana-
lytical grade (Merck, Darmstadt, Germany). The water was purified
with a Milli-Q Academic system (Millipore, Bedford, MA, USA).
2.2. Liposome preparation and characterization
Two formulations of GSH-PEG liposomal MTX containing either
HSPC or EYPC as well as their corresponding PEG control liposomes
without GSH were prepared using an ethanol injection method with
post-insertion of GSH-PEG micelles or PEG micelles. In brief, the lipids
including 100 mM phospholipids, either HSPC or EYPC, 66 mM cho-
lesterol and 1.7 mM mPEG2000-DSPE (1 mol%), were dissolved in
4.8 mL absolute ethanol and then mixed with 15.2 mL MTX solution
(50 mg/mL, diluted from the original MTX injection solution with
saline) at 60 °C. The formed liposomes were extruded step-wise through
400/200 nm, 200/200 nm, 200/100 nm and 100/100 nm Whatman
filters (Instruchemie, Delfzijl, the Netherlands) to reduce and unify the
particle size. GSH and DSPE-PEG2000-maleimide (4 mol%) were in-
cubated at a 1.5:1 M ratio for 2 h at room temperature to form GSH-
PEG-DSPE micelles. PEG-DSPE micelles were also made by incubating
mPEG2000-DSPE (4 mol%) under the same condition. GSH-PEG-DSPE
or PEG-DSPE micelles for PEG control liposomes were post-inserted to
the liposomes at 60 °C for 2 h. The final total molar percentage of PEG
in the liposomes was 5%, with 4% GSH-PEG-DSPE and 1% PEG-DSPE
for GSH-PEG liposomes, or with 4% PEG-DSPE post-inserted and 1%
PEG-DSPE pre-inserted for PEG control liposomes. After post-insertion
of the micelles, the liposomes were purified via ultrafiltration using a
Pellicon XL 50 Cassette ultrafiltration column equilibrated with saline
on a Cogent® μScale Tangential Flow Filtration System (Merck
Millipore) to remove non-encapsulated MTX and excess GSH. The
purified liposomes were sterile filtered using 0.2 µm filters, and aliquots
were stored at 4 °C until further use.
The size of the liposomes was measured using a Malvern Zetasizer
Nano ZS90 (Malvern Instruments, Worcestershire, UK). The en-
capsulated MTX was determined using an HPLC-UV assay after re-
leasing the drug from the liposomes with ACN. In short, chromato-
graphic separation was carried out on a Xbridge C18 column
(150 × 4.6 mm, 3.5 μm) (Waters, CA, USA) using a Shimadzu 20A
ultra-fast liquid chromatography system (Shimadzu, Kyoto, Japan)
under isocratic elution with a flow rate of 1 mL/min and the column
temperature of 23 °C. The mobile phase consisted of ACN: buffer (10:90,
v/v) of which the buffer is the mixture of disodium hydrogen phosphate
and citric acid (63:37, v/v). The UV wavelength for detection was set at
302 nm. The lipid levels in the liposomes were quantified using HPLC
combined with evaporative light-scattering detection (ELSD) (Alltech,
the Netherlands). A Kinetex C18 (150 × 4.6 mm, 2.6 μm, Phenomenex)
column equipped with a guard column was used for analysis of HSPC,
EYPC, cholesterol, GSH-PEG-DSPE and PEG-DSPE. The column tem-
perature was set to 45 °C. All lipids were chromatographically separated
within 30 min under a gradient elution of mobile phase A (0.1 M am-
monium acetate, pH 6.0) and 90–100% mobile phase B (methanol) at a
flow rate of 1.5 mL/min. For the ELSD, the nitrogen gas flow was set to
1.5 mL/min and temperature in the drift tube was 80 °C.
2.3. In vitro stability of liposomes
The liposome stability in both phosphate buffer saline (PBS) and rat
plasma was evaluated. For the experiment, 10 µL solution of each li-
posomal formulation was diluted with 40 µL of either PBS or rat plasma
and then incubated at 37 °C for 48 h. During the incubation, samples
were taken at 0, 1, 2, 4, 8, 24 and 48 h. The collected sample was di-
luted with 150 µL PBS before loading 100 µL of the diluted sample onto
a Zebaspin desalting column (Thermo Scientific, Rockford, IL, USA)
equilibrated with PBS. After removal of potentially released MTX, ACN
was added to the purified sample to release the encapsulated MTX. The
concentrations of MTX were analyzed using the abovementioned HPLC-
UV method. The amount of liposomal MTX at each time point was
expressed as the percentage of the value at time 0 (T0).
2.4. Animals
Male Sprague Dawley rats, obtained from Taconic (Lille Skensved,
Denmark) were used throughout the experiment. Before the experi-
ments, the rats were housed in groups and acclimatized for 7 days under
temperature- and humidity-controlled conditions in a 12 h light/dark
cycle with unlimited access to food and water. The rats weighed
230–290 g on the day of the experiment. The experimental protocols
and animal procedures were approved by the Uppsala Regional Animal
Ethics Committee, Uppsala, Sweden (C13/14).
2.5. Surgery
The rats were anesthetized during the surgery by inhaling 2.5%
isoflurane (Isoflurane Baxter®, Baxter Medical AB, Kista, Sweden),
combined with 1.5 L/min oxygen and 1.5 L/min nitrous oxide. The
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body temperature was kept at 38 °C using a heating pad (CMA/150
temperature controller, CMA, Stockholm, Sweden). Pre-heparinized
(100 IU/mL heparin in saline) PE-50 cannulas (MicLev, Malmö,
Sweden) were inserted into the left femoral artery for blood sampling
and into the left and right femoral vein for drug/liposomes adminis-
tration. In order to measure the released, unbound MTX concentrations
in blood, a flexible CMA/20 microdialysis probe with 10 mm poly-
arylethersulfone (PAES) membrane and 20 kD cut-off (CMA,
Stockholm, Sweden) was implanted into the right jugular vein and fixed
to the pectoral muscle by two sutures. For sampling in brain interstitial
fluid (ISF), a CMA/12 guide cannula was initially inserted into the
striatum (position: 2.7 mm lateral and 0.8 mm anterior to the bregma
and 3.8 mm ventral to the brain surface) using a stereotaxic instrument
(David Kopf Instruments, Tujunga, USA) and secured to the skull with a
screw and dental cement (Dentalon® Plus Heraeus, Germany).
Subsequently, the guide cannula was carefully replaced by a CMA/12
probe with 3 mm PAES membrane and 20 kD cut-off (CMA, Stockholm,
Sweden). All catheters were passed subcutaneously to the posterior
surface of the neck. After surgery, the rat was individually placed in a
CMA/120 system for freely moving animals and allowed to recover for
24 h before the start of the experiment, which was performed on awake
animals.
2.6. In vivo quantitative study design
On the experiment day, the microdialysis probes were perfused with
Ringer solution containing MTX-D3 as the recovery calibrator. The
concentrations of MTX-D3 in brain and blood perfusate were 20 and
200 ng/mL, respectively. The rate of perfusion was maintained at
0.5 µL/min using a CMA/100 precision infusion pump (CMA,
Stockholm, Sweden). In order to stabilize the system, the perfusion
started at least 90 min before the beginning of drug administration.
Fluorinated ethylene propylene (FEP) tubings (CMA, Stockholm,
Sweden) were used as both inlet and outlet tubings. The in vivo probe
recovery was determined throughout the whole experiment based on
retrodialysis [17].
To compare the pharmacokinetic (PK) profiles between free MTX
and liposomal formulations, the rats were randomly assigned to five
groups: GSH-PEG-HSPC liposomes (referred to as “GSH-PEG-HSPC”)
(n = 7), PEG-HSPC liposomes (referred to as “PEG-HSPC”) (n = 7),
GSH-PEG-EYPC liposomes (referred to as “GSH-PEG-EYPC”) (n = 7),
PEG-EYPC liposomes (referred to as “PEG-EYPC”) (n = 7) and free MTX
(n = 4). For the liposomal groups, the rats received 30-min intravenous
administration of the four formulations at the same MTX dose (15 mg/
kg) through the left femoral vein using a Harvard 22 pump (Harvard
Apparatus Inc., Holliston, MA). In order to achieve comparable steady-
state unbound MTX concentrations in plasma after administering free
MTX and liposomal formulations, a pilot study was performed to de-
termine the doses needed in the “free drug group”. The free MTX was
intravenously administered as a loading dose of MTX (7.2 µg/min/kg)
during the initial 0.5 h, followed by a 9.5 h constant infusion (6 µg/
min/kg). After observing an increased unbound brain-to-plasma con-
centration ratio after administration of GSH-PEG-HSPC compared to
PEG-HSPC and free MTX in the pilot study, a co-administration group
was additionally included (n = 4). In this group, free MTX (same dose
regimen as the “free drug group”) and empty GSH-PEG-HSPC liposomes
(same HSPC dose as GSH-PEG-HSPC) were simultaneously injected into
the left and right venous catheters, respectively. The reason for adding
this group was to examine if GSH-PEG-HSPC liposomes themselves may
influence the BBB integrity, function and thereby the uptake of MTX.
The microdialysate fractions were collected from blood and brain
ISF every 30 min (∼15 μL per fraction) in polypropylene vials
(AgnThos, Lidingö, Sweden), starting from 1 h before the infusion
started until 10 h after the beginning of the infusion. All the sampling
vials were weighed before and after sample collection to monitor the
flow through the probe during the experiment. The midpoint time in
each collection interval was used to plot the concentration-time curves.
Blood (∼200 μL) was withdrawn into heparinized polypropylene tubes
at pre-dose, 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 10 and 24 h after the start of
the infusion. The collected blood samples were immediately centrifuged
at 10000 rpm (7200g) for 5 min, after which the plasma was transferred
to clean polypropylene tubes. All microdialysis and plasma samples
were stored at −20 °C until further analysis.
2.7. Sample analysis
An ultra-performance liquid chromatography-tandem mass spec-
trometry (UPLC-MS/MS) method was employed to quantify MTX and
MTX-D3 in microdialysate and plasma. The plasma sample obtained
from the liposomal groups (2.5 μL) was first diluted 20-fold with blank
rat plasma, followed by protein precipitation with 150 μL of ACN
containing 1% formic acid (FA) and MTX-D3 as the internal standard
(IS). The plasma sample (50 μL) from the free MTX and co-adminis-
tration groups was directly precipitated by adding 150 μL of IS- and FA-
containing ACN. After centrifugation for 3 min at 13,000 rpm, an ali-
quot of 10 µL of the supernatant was diluted with 400 µL of 0.01% FA in
10% ACN (mobile phase A), before injecting 5 μL onto the UPLC-MS/
MS system. For brain and blood microdialysate, a volume of 10 μL
sample was mixed with 90 μL mobile phase A. Then, 5 μL of the diluted
sample was injected onto the UPLC-MS/MS system.
Chromatographic separation was performed on an ACQUITY BEH
C18 column (50 × 2.1 mm, 1.7 μm) protected by an ACQUITY BEH C18
guard column (10 × 2.1 mm, 1.7 μm) (Waters, CA, USA) using a Waters
ACQUITY UPLC system (Waters, CA, USA). The mobile phase consisted
of 0.01% FA in 10% ACN (A) and 0.01% FA in 90% ACN (B). The
gradient elution started at 0% B for 1 min, then increased linearly to
90% B within 1 min and kept at 90% B for 0.5 min, before returning to
0% B for equilibration. The flow rate was 0.3 mL/min and the total run
time was 3 min. A Quattro Ultima triple quadrupole mass spectrometer
was used for MS/MS detection (Waters, Milford, MA, USA), and
MassLynx software version 4.1 (Waters, Milford, MA, USA) was utilized
for data acquisition and processing. The detection of MTX and MTX-D3
was performed in a positive electrospray mode using multiple reaction
monitoring transitions of m/z 455.2 → 308.0 for MTX and m/z 458.3 →
311.0 for MTX-D3. The linearity range for plasma samples was between
5 and 20000 ng/mL. For microdialysis samples, the standard curves for
both MTX and MTX-D3 ranged from 0.1 to 500 ng/mL. By using 1/x2
weighing, the coefficient of determination (R2) for all the standard
curves was higher than 0.99. The precision and accuracy for quality
controls were below 15% coefficient of variation (CV) in all runs.
2.8. Data analysis






where Ccalibrator,in is the concentration of MTX-D3 in the microdialysis
perfusate determined in triplicates before and after the experiment and
Ccalibrator,out is the average concentration of MTX-D3 in the collected
dialysate during the experiment.
Adsorption of both MTX and MTX-D3 to the probes or tubings was
negligible. The recovery of the microdialysis probes was stable
throughout the experiments. The average recovery was 0.09 ± 0.05
and 0.57 ± 0.14 for the brain and the blood probes, respectively.
The unbound concentration (Cu) of MTX in brain ISF and plasma






where Cdialysate is the concentration of MTX in the collected dialysate
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and recovery is the average of individual recovery measured from all
brain or blood probes.
According to non-compartmental analysis, the clearance (CL) of
MTX after administration of free MTX, liposomal MTX or free
MTX + empty liposomes was estimated in two ways:





For the liposomal groups:
=CL Dose
AUC0 (4)
where R0 is the infusion rate of free MTX with or without empty lipo-
somes and Ctot,ss,plasma is the steady-state plasma concentration of MTX.
The AUC0→∞ is the area under the concentration-time curve of total
MTX (released and encapsulated) in the four liposomal groups, calcu-
lated using the linear trapezoid method. The residual areas for AUC0→∞
were calculated as Clast/λz, where Clast is the concentration measured at
24 h and λz is the terminal rate constant estimated from the slope of the
4 last concentrations measured. For the liposomal groups, the terminal
half-life (t1/2) and the volume of distribution (Vd) were calculated as ln
(2)/λz and CL/λz, respectively.
The unbound fraction of MTX in plasma (fu) after administration of
free MTX or free MTX + empty liposomes was calculated as Cu,ss,plasma/
Ctot,ss,plasma, where Cu,ss,plasma and Ctot,ss,plasma represent the concentra-
tion of unbound and total MTX in plasma at steady state, obtained from
the microdialysis and plasma samples collected 1–10 h after the start of
the administration. For the liposomal groups, Cu,ss,plasma/Ctot,ss,plasma
was also calculated based on the microdialysis and plasma samples
collected 8–10 h after infusion started to describe the extent of in vivo
drug release.
The brain delivery of MTX was described by the ratio of unbound







where Cu,ss,brain and Cu,ss,plasma represent the steady-state concentrations
of unbound MTX in brain and plasma, respectively, obtained from the
brain and plasma microdialysate collected 8–10 h after the start of the
infusion.
Statistical analyses were performed using R version 3.5.0 [20] using
the multicomp package [21]. Differences between the groups were as-
sessed using a linear model with the log-transformed ratio as the de-
pendent variable. Assumptions of constant variance and normality of
the residuals were checked visually using quantile-quantile plots of the
residuals versus quantiles from a normal distribution and plots of re-
siduals versus fitted values. Multiplicity adjusted p-values were calcu-
lated taking the correlations of the individual test statistics into account
which is more efficient than the usual Bonferroni adjustment [22]. A
*p < 0.05 was considered to be statistically significant.
3. Results
For all liposomal formulations, the size, polydispersity index (PDI),
encapsulated MTX and lipids concentrations were measured and are
presented in Table 1. All formulations were comparable in size and
MTX contents. For both GSH-PEG-HSPC and GSH-PEG-EYPC liposomes,
the presence of GSH-PEG lipid confirmed successful conjugation of GSH
on the surface of the liposome. After the incubation in either PBS or rat
plasma for 48 h, no significant differences in the levels of liposomally
encapsulated MTX were observed for any of the liposomal formulation
relative to their initial values (Fig. 1), suggesting that all the formula-
tions had excellent stability in vitro.
In the free MTX (Fig. 2A) and co-administration group (Fig. 2D), a
steady state of total plasma concentration was reached within 1 h after
a loading dose was given. The total plasma CL of MTX was comparable
regardless of whether or not empty GSH-PEG-HSPC was co-adminis-
tered together with the free drug (Table 2).
After 30-min infusion of the four liposomal formulations at the same
doses, the total plasma concentrations of MTX were similar in-
dependent of the formulation administered and were very stable up to
10 h with long half-lives ranging from 22 to 27 h (Fig. 2B, C, E and F
and Table 2). Also, the CL of total MTX in plasma was naturally much
lower than that observed when administering free MTX either with or
without empty GSH-PEG-HSPC liposomes.
The unbound fraction of MTX in plasma was similar when free MTX
was administered by itself or co-administered with empty GSH-PEG-
HSPC liposomes (Table 2). The total plasma concentration of MTX,
including both released and liposomally encapsulated MTX, was
717–4330 times higher than the unbound MTX concentration in plasma
in the liposomal groups (Table 3, Fig. 2B, C, E, and F). The four lipo-
somal formulations released MTX to different extents, as reflected by
the different ratios of unbound to total MTX in plasma. In general, the
extent of MTX release in plasma was significantly greater from EYPC-
based than from HSPC-based formulations (p < 0.05). However, there
Table 1
Characteristics of liposomal MTX.
Sizea (PDI) Concentration (mg/mL)
MTX HSPC EYPC Cholesterol PEG GSH-PEG
GSH-PEG-HSPC liposomes 126.3 (0.074) 4.8 27.3 – 7.7 1.5 9.4
GSH-PEG-EYPC liposomes 122.6 (0.089) 5.4 – 36.0 7.4 2.2 9.3
PEG-HSPC liposomes 126.3 (0.064) 5.5 37.4 – 7.2 14.2 –
PEG-EYPC liposomes 119.1 (0.105) 5.8 – 54.6 7.0 20.5 –
a Size in nanometers.
Fig. 1. In vitro stability of liposomal MTX formulations in PBS or rat plasma at
37 °C. (n = 3).
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were no significant differences between GSH and non-GSH formulations
containing either HSPC or EYPC (Table 3).
The transport of free MTX at the BBB was very limited, reflected by
a Kp,uu of 0.10 ± 0.03 (Table 2, Fig. 3A, B and C). The co-adminis-
tration of empty GSH-PEG-HSPC together with free MTX did not sig-
nificantly influence MTX transport at the BBB compared with admin-
istering free MTX alone (Table 2, Fig. 3A and C).
Compared with administering free MTX, PEG-HSPC did not sig-
nificantly affect brain uptake of MTX. PEG-EYPC on the other hand
resulted in a significant improvement in uptake with a 15-fold increase
in Kp,uu to 1.5, although with a large variability (p < 0.05) (Table 2
and Fig. 3C). The addition of GSH on PEG-EYPC did not lead to further
enhancement in brain delivery of MTX (Table 2 and Fig. 3B and C).
Compared to PEG-HSPC, GSH-PEG-HSPC significantly increased the
Fig. 2. Observed concentration-time profiles of unbound MTX in brain ISF (open triangles), unbound (open circles) and total MTX (filled circles) in plasma after i.v.
administration of free MTX, liposomal MTX or free MTX + empty liposomes. (A) Free MTX (n = 4), (B) PEG-EYPC (n = 7), (C) GSH-PEG-EYPC (n = 7), (D) free
MTX + empty GSH-HSPC-HSPC (n = 4), (E) PEG-HSPC (n = 7), (F) GSH-PEG-HSPC (n = 7). Data are presented as Mean ± SD.
Table 2
Estimated PK parameters of MTX in rats after the administration of free MTX, liposomal MTX or free MTX + empty liposomes. The calculation of CL, Vd and t1/2 are
based on total plasma concentrations. Data are presented as Mean ± SD.
Parameters Administration groups
Free MTX Free MTX + empty GSH-PEG-HSPC PEG-HSPC GSH-PEG-HSPC PEG-EYPC GSH-PEG-EYPC
CL (mL/h/kg)§ 1240 ± 312 1030 ± 385 1.35 ± 0.28 1.90 ± 0.30 1.39 ± 0.28 1.71 ± 0.57
Vd (mL/kg)§ – – 49.0 ± 7.3 58.7 ± 5.9 49.6 ± 5.2 53.7 ± 6.2
t1/2 (h)§ – – 27.0 ± 11.3 21.9 ± 4.5 25.5 ± 5.0 25.3 ± 13.7
fu 0.76 ± 0.09 0.69 ± 0.07 – – – –
Kp,uu 0.10 ± 0.03 0.09 ± 0.05 0.23 ± 0.17 0.82 ± 0.59*,# 1.5 ± 1.0* 0.53 ± 0.29*
§ The residual areas for the liposomal formulations were 25–73% due to the very long half-lives.
* p < 0.05 indicates a significantly higher Kp,uu compared with free MTX.
# p < 0.05 indicates a significantly higher Kp,uu compared with PEG control liposomes.
Table 3
Steady-state total plasma, unbound plasma and unbound brain concentrations of MTX after administering free MTX, liposomal MTX or free MTX + empty liposomes,
unbound-to-total and total-to-unbound plasma concentration ratios after administering liposomal MTX. Data are expressed as Mean ± SD.
Variable MTX concentration (ng/mL)
Free MTX Free MTX + empty GSH-PEG-HSPC PEG-HSPC GSH-PEG-HSPC PEG-EYPC GSH-PEG-EYPC
Total plasma 305 ± 80 394 ± 158 243000 ± 31300 192000 ± 21400 230000 ± 24500 204000 ± 23700
Unbound plasma 249 ± 32 213 ± 47 55.0 ± 9.2 111 ± 42 290 ± 87 292 ± 43
Unbound brain 23.5 ± 6.0 18.3 ± 8.2 11.8 ± 8.2 74.1 ± 43.7 360 ± 224 158 ± 95
Cu,ss,plasma/Ctot,ss,plasma 0.00024 ± 0.00005 0.00058 ± 0.00023 0.0013 ± 0.0004& 0.0015 ± 0.0003&
Ctot,ss,plasma/Cu,ss,plasma 4330 ± 826 2010 ± 819 855 ± 273 717 ± 162
& p < 0.05 indicates a significantly higher extent of MTX release in plasma compared with HSPC-based formulations.
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uptake of MTX into the brain with the Kp,uu increasing to 0.82
(p < 0.05) (Table 2 and Fig. 3C). Also, the brain uptake was increased
early after administration (Fig. 3A).
4. Discussion
Our study for the first time shows that the brain-targeting effect of
GSH-PEG liposomal MTX is highly dependent on the liposomal for-
mulation that is combined with GSH. While GSH-PEG-HSPC sig-
nificantly improved the brain uptake of MTX by 4-fold compared to the
non-targeted control PEG-HSPC, conjugation of GSH to PEG-EYPC did
not result in a further increase in uptake. However, PEG-EYPC in itself
showed significantly improved uptake compared with free MTX.
All four liposomal formulations gave similar total MTX levels in
plasma that declined very slowly, independent of if they were based on
HSPC or EYPC. This shows that all formulations were equally stable in
vivo, confirming the results from the in vitro stability test, consistent
with the results in our previous study [16]. The addition of GSH to
either PEG-HSPC or PEG-EYPC did not make any difference in total
plasma PK of MTX. This was in line with previous literature showing
that GSH coating has no impact on the PK properties of the total drug in
plasma compared to PEG control liposomes [10,11].
In order to fully map the behavior of nanoformulations in vivo and to
more thoroughly understand possible improvement in brain uptake by
the formulation, it is of importance to not only measure the total con-
centrations in plasma (mostly liposome-encapsulated and not available
for the target) but also the concentrations of released, unbound drug
(related to efficacy/toxicity). The use of microdialysis in blood suc-
cessfully separated the released MTX from the drug remaining en-
capsulated, thus making it possible to continuously monitor the in vivo
drug release from all formulations. In spite of similar total concentra-
tions, PEG-EYPC released MTX faster in plasma than PEG-HSPC, as
reflected by the significantly higher unbound-to-total plasma con-
centration ratio, and 5.3-fold higher unbound plasma concentration of
MTX (Table 3). Our previous paper also showed faster MTX release
from EYPC than HSPC based PEG liposomes [16]. However, the un-
bound-to-total plasma concentration ratios for both formulations were
different between two studies (for PEG-HSPC: 0.00024 vs. 0.0007 and
for PEG-EYPC: 0.0013 vs. 0.007 in the previous paper). The discrepancy
in the extent of in vivo MTX release can likely be attributed to different
PEGylation methods used in the two studies. Previously, 5% PEG was
incorporated into both HSPC and EYPC based PEG liposomes using the
pre-insertion method, which led to about half of the PEG being oriented
outward from the membrane and the rest toward the inside of the li-
posomes [23]. In the current study, 4% PEG was post-inserted, leading
to PEG being present mainly on the outer side of the liposomes, with
around 4.5% PEG presented on the surface and 0.5% PEG facing in-
wards, including the 1% PEG pre-inserted. It can be speculated if dif-
ferent density of PEG on the inner and outer surfaces of the liposomes
may influence the properties of liposome bilayers and consequently
affect the in vivo release extent. The lack of significant difference in
unbound-to-total concentration ratios in plasma between GSH-PEG and
PEG control formulations suggests that GSH-coating did not influence
the release properties of MTX in plasma regardless of the formulation
used, consistent with the observations from a previous study [15].
Free MTX crossed the BBB to a very limited extent with a Kp,uu being
0.1, confirming the findings from our previous study [16]. Also, similar
to our previous results, PEG-HSPC did not significantly affect the
transport of MTX at the BBB compared with administrating free MTX.
However, unlike the 3-fold improvement in brain delivery of MTX re-
lative to free MTX when PEG-EYPC liposomes were administered pre-
viously [16], we observed an even more substantial increase in Kp,uu of
MTX from 0.1 to 1.5 in this study from the PEG-EYPC group, in spite of
a large variability. This finding is not consistent with a previous study
showing that the increase in PEG density on nanoparticles decreased
cellular uptake [24]. Currently, we do not have an explanation for this
discrepancy. Despite this, the considerable increase of Kp,uu from 0.1 to
a value around unity was in itself an intriguing finding, indicating that
the efflux transport of MTX might have been neutralized when deli-
vering with PEG-EYPC liposomes.
GSH-PEG-EYPC did not result in a further increase in brain uptake
compared to PEG-EYPC. Despite using a different payload (DAMGO, an
opioid peptide), similar results were observed in a previous study where
both GSH-PEG-EYPC and PEG-EYPC liposomes doubled brain uptake of
DAMGO compared with administering free DAMGO without any sig-
nificant difference in uptake between two formulations [15]. These
results indicate that PEG-EYPC liposomes may not be a suitable for-
mulation to be combined with GSH in order to achieve improved brain
targeting delivery. On the contrary, PEG-EYPC liposomes seem to be
able to improve brain drug delivery by themselves without the need of
GSH. The most probable mechanism by which PEG-EYPC liposomes
facilitated drug transport at the BBB was earlier interpreted as being a
fusion of the liposomes with the endothelial luminal membrane [25].
When GSH was combined with PEG-EYPC, it can be speculated that
GSH-mediated uptake may be dominated by the fusion process asso-
ciated with PEG-EYPC, thus making the brain-targeting effect of GSH-
PEG-EYPC not observable. Further mechanistic studies are required to
elucidate the reason behind this phenomenon.
Unlike GSH-PEG-EYPC, GSH-PEG-HSPC significantly enhanced the
transport of MTX at the BBB by 4-fold compared to its PEG control
formulation and 8-fold compared to free MTX. In line with these results,
previous studies have shown that GSH-PEG liposomes were superior to
Fig. 3. (A) Unbound brain-to-plasma concentration ratios over time after 30 min i.v. infusion of free MTX, free MTX + empty PEG liposomes, PEG-HSPC or GSH-PEG-
HSPC. Data are expressed as mean ± SEM, n = 4–7. (B) Unbound brain-to-plasma concentration ratios over time after 30 min i.v. infusion of free MTX, PEG-EYPC or
GSH-PEG-EYPC. Data are presented as mean ± SEM, n = 4–7. (C) Steady-state unbound brain-to-plasma concentration ratio (Kp,uu) for the six groups. *p < 0.05
indicates significantly higher Kp,uu compared with free MTX, #p < 0.05 indicates significantly higher Kp,uu compared with PEG control liposomes. n = 4–7.
Comparisons were made based on the data between 8 and 10 h.
Y. Hu, et al. European Journal of Pharmaceutics and Biopharmaceutics 139 (2019) 197–204
202
plain PEG liposomes in delivering ribavirin, doxorubicin, methyl-
prednisolone and carboxyfluorescein into the brain when HSPC was
used as the main phospholipid [9–11,14,26]. Similar brain uptake was
found regardless of whether free MTX was administered alone or to-
gether with empty GSH-PEG-HSPC liposomes. This observation ex-
cludes any possibility that GSH-PEG-HSPC liposomes themselves in-
fluence the BBB integrity or function. Moreover, as shown from Cu,brain/
Cu,plasma ratio with time (Fig. 3A and B), the EYPC based formulations
gradually increased the brain uptake of MTX, while the GSH-PEG-HSPC
formulation resulted in a much quicker increase in the uptake. There-
fore, the increased brain delivery of MTX when using GSH-PEG-HSPC is
indicative of a GSH-mediated targeting process, rather than non-spe-
cific interaction between liposomes and the BBB. The observation that
PEG-HSPC liposomes did not at all influence the brain uptake compared
with free MTX likely indicates that a fusion process like the one pro-
posed for PEG-EYPC liposomes is not present for PEG-HSPC. Thus, GSH-
mediated targeting is the most likely process for GSH-PEG-HSPC lipo-
somes.
The therapeutic success of liposomal brain delivery is not solely
dependent on the increase in Kp,uu but is influenced by multiple factors.
These factors include loading capacity, final drug concentration in li-
posome solution, volume allowed to be administered in vivo, release
rate, improvement in brain delivery, attainable concentration at the
target site to obtain clinical effects versus off-target site concentration
to see side effects, and potency of the drug. Properties like high drug
loading, appropriate release rate, large enough increase in Kp,uu and
high enough potency are favored and often needed to come together in
order for liposomal delivery to be therapeutically successful at the CNS
target. The half-life of the formulation is also of importance for ther-
apeutic success. If administering free MTX with its short half-life and
Kp,uu of 0.1, in order to maintain an unbound brain concentration at
therapeutic level, a constant infusion would have to be given to obtain a
steady-state unbound plasma concentration of 4500 ng/mL. However, if
GSH-PEG-HSPC or PEG-EYPC is administered, only a 30-min short in-
fusion with a much lower steady-state unbound plasma concentration
of 563 or 300 ng/mL, respectively, would be adequate. This is due to a
prolonged half-life, sustainable drug release and greatly improved Kp,uu
when administering liposomal MTX. Therefore, when having similar
central efficacy, delivery of MTX with certain liposomal formulations
would have less risk of peripheral toxicity compared to giving free MTX.
Taking this study as an example, although GSH-PEG-HSPC sub-
stantially improved the Kp,uu of MTX compared to PEG-HSPC and un-
formulated MTX, with an infusion volume of 0.94 mL, the resulting
brain ISF concentration of MTX at steady-state was around 74 ng/mL
(Table 3). This is much lower than the reported minimal effective
concentration to kill tumor cells (450 ng/mL, or > 100 nM) [27]. Even
if the maximal volume of 2 mL allowed to be administered to rats had
been given, theoretically the brain ISF concentration would increase to
157 ng/mL, which would still not be sufficient to be therapeutically
effective with a single administration. When the same MTX dose was
administered in PEG-EYPC liposomes (infusion volume 0.77 mL), this
resulted in a much higher brain ISF concentration of 360 ng/mL, which
is a result of higher unbound-to-total plasma concentration ratio
(0.0013 vs 0.00058) as well as higher Kp,uu (1.5 vs 0.8) than the GSH-
PEG-HSPC formulation. If 2 mL had been infused, the unbound brain
concentration would have reached therapeutic level. From a safety
window perspective, although PEG-EYPC has a better brain delivery,
there may still be a concern for more peripheral side effects due to
higher unbound plasma concentrations. Therefore, all these factors
need to be taken into consideration when formulating a liposomal
strategy for in vivo delivery to the brain.
5. Conclusions
Our study demonstrates that the brain-targeting effect of GSH-PEG
liposomes, using MTX as the model drug, relies highly on the liposomal
formulation that is combined with GSH. Compared to the PEG control
formulations, GSH-PEG-HSPC increased brain delivery of MTX 4-fold
(8-fold compared to free MTX), while the addition of GSH on PEG-EYPC
did not result in a further enhancement of brain uptake. On the other
hand, PEG-EYPC was in itself improving uptake 15-fold (5-fold with
GSH-PEG-EYPC), yet with higher unbound plasma concentrations.
Since co-administration of empty GSH-PEG-HSPC liposomes with free
MTX did not affect uptake, the improved brain delivery was not caused
by liposomes themselves influencing BBB integrity or function, but
more likely a consequence of a GSH-mediated process. This work dee-
pens the understanding of how liposomal formulations could influence
the outcomes of brain-targeted delivery of GSH-PEG liposomes, high-
lighting the central role of formulation optimization when developing
this promising brain delivery technology to treat CNS diseases. Since a
brain-specific targeted delivery of drugs (as seen by the GSH-PEG li-
posomes using HSPC) is generally considered to be preferred for overall
successful clinical drug development over a non-specific tissue delivery
(as seen by the PEG liposomes using EYPC), we conclude that finding
the optimal dosing schedule of the GSH-PEG liposomes using HSPC is
the preferred way forward for MTX delivery to the CNS.
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